Protocol: Bevacizumab Treatment for Type 1 Retinopathy of Prematurity
Status: Recruiting
Start Date: 10/14/2021
End Date:  
Clinical Trial ID: NCT04634578
Public Dataset:  

 



ROP4 - Bevacuzumab Treatment for Type 1 Retinopathy Of Prematurity

 

Protocol

Primary Objective:

  • The primary objective of the current protocol is to evaluate whether doses of 0.063 mg and 0.25mg are effective as treatment for type 1 ROP, with ROP and retinal vessels all in zone I. Secondary objectives are to compare 1) safety and efficacy, 2) refractive outcomes, and 3) the extent of retinal vascularization at 4 months post-injection between the two dose groups.


Back